Overview

Description

  • NatureSynthetic
  • Amino Acid Sequence
    • SpeciesHuman
    • SequenceC-TAEKTKRVSTKEI
    • Amino acids296 to 308

Associated products

Specifications

Our Abpromise guarantee covers the use of ab23213 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-FSTL1 antibody (ab11805)

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

General Info

  • Alternative names
    • Anti FSTL1
    • FLJ50214
    • FLJ52277
    • Follistatin like 1
    • Follistatin related protein
    • Follistatin-like protein 1
    • Follistatin-related protein 1
    • FRP
    • FSL1
    • FSTL1
    • FSTL1 antibody
    • FSTL1_HUMAN
    • Micro RNA 198
    • MIR198
    • miRNA198 included
    see all
  • FunctionMay modulate the action of some growth factors on cell proliferation and differentiation. Binds heparin.
  • Tissue specificityOverexpressed in synovial tissues from rheumatoid arthritis.
  • Sequence similaritiesContains 2 EF-hand domains.
    Contains 1 follistatin-like domain.
    Contains 1 Kazal-like domain.
    Contains 1 VWFC domain.
  • Cellular localizationSecreted.
  • Information by UniProt

References for Human FSTL1 peptide (ab23213)

This product has been referenced in:
  • Adams DC  et al. Follistatin-like 1 regulates renal IL-1{beta} expression in cisplatin nephrotoxicity. Am J Physiol Renal Physiol 299:F1320-7 (2010). Blocking . Read more (PubMed: 20861081) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab23213.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"